Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Rhea-AI Summary

Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.

Positive

• The meeting will reconvene promptly, minimizing delays for shareholders.
• Stockholders retain the ability to vote and participate virtually, ensuring continued engagement.

Negative

• Technical difficulties disrupted the planned meeting, potentially undermining investor confidence.
• No business was conducted during the originally scheduled meeting, causing an operational delay.

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time 

PHILADELPHIA, June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site. The meeting will be reconvened at 10:00 a.m. Eastern Time on Friday, June 14, 2024.

Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-adjournment-of-annual-meeting-of-stockholders-302172413.html

SOURCE Carisma Therapeutics Inc.

FAQ

Why was Carisma Therapeutics' annual meeting adjourned on June 13, 2024?

The annual meeting was adjourned due to technical difficulties with the third-party hosting site.

When will Carisma Therapeutics' annual stockholder meeting reconvene?

The meeting is rescheduled to reconvene on June 14, 2024, at 10:00 a.m. Eastern Time.

How can Carisma Therapeutics stockholders participate in the rescheduled meeting?

Stockholders can attend the virtual meeting online, vote electronically, and submit questions via a virtual audio web conference at https://meetnow.global/MAJJ4AY.